Key Performance Indicators and Performance in Relation to the GRI and ATMI

In preparing Merck's disclosures relating to access to medicines performance, we have referred to the Access to Medicines Index (ATMI). This index is a first step toward a useful framework for transparent reporting about access to medicines performance, which will help inform our stakeholders and also enable us to compare our performance with peers on relevant metrics. We believe that this will help us focus on continuously improving the things that matter most. The table below summarizes where Merck disclosures can be found on the Merck website in relation to the ATMI criteria.

Management
ATMI Criterion		Addressed on merck.com/cr
A1	Governance: The company has a governance system that includes direct board level responsibility and accountability for its AtM strategy	Improving Access to Medicines, Vaccines and Health Care
A2	Policy and Disclosure: The company has a public global policy in place, in which it explains its rationale for AtM, its contents and details its specific objectives	Improving Access to Medicines, Vaccines and Health Care
A3	Systems and Reporting: The company has a management system, including quantitative targets, to implement, monitor and report on its AtM strategy	Improving Access to Medicines, Vaccines and Health Care
A4	Stakeholder Input: The company has a mechanism for stakeholder engagement which inputs into AtM management	External Stakeholder Input on Reporting Approach
A5	The company has globally applicable ethical business practices and marketing policies that conform to appropriate standards	Conducting Ourselves Ethically and Transparently Ethical Sales and Marketing Practices
Public Policy
B1	The company has a position on public policy advocacy and transparency	Advocating For and Disclosing Public Policies
B2	The company and subsidiaries disclose major public policy positions at regional, national and international levels related to the AtM debate	Improving Access in the Developing World and Emerging Markets (public policy) Advocating for and Disclosing Public Policies
B3	The company and subsidiaries actively advocate health reforms that foster AtM and policies that would result in improvements in public health	Improving Access in the Developing World and Emerging Markets Public Policy and Advocacy Related To Access in the Developed World
B4	The company annually discloses which individuals, patient associations, political parties, trade associations, academic departments it supports and with which it advocates on public policy positions and practices regional, national and international level	Advocating For and Disclosing Public Policies
B5	The company demonstrates a process of board approval of the approach to public policy advocacy, its transparency, and reporting	Advocating For and Disclosing Public Policies
Research & Development
C1	The company has a policy on R&D investment that reflects both the global disease burden and neglected diseases	Researching New Medicines and Vaccines to Address Unmet Needs Our Research Agenda In Relation To Developing World Needs
C2	The company provides evidence of in-house investment in R&D into new treatments for neglected diseases	Our Research Agenda In Relation To Developing World Needs
C3	The company with in-house investment in R&D into new treatments for neglected diseases provides evidence of partnership with groups with developing-country health expertise, such as product development PPPs, academic institutions and/or the WHO	Our Research Agenda In Relation To Developing World Needs
C4	The company shows temporal evidence that its research programs into both the global disease burden and neglected diseases consider research into existing medicines and formulations suitable for use in developing and least developed countries and for affected patient groups	Researching New Medicines and Vaccines to Address Unmet Needs Our Research Agenda In Relation To Developing World Needs
Patents and Licensing
D1	The company demonstrates the existence of, and discloses the terms of, nonexclusive voluntary license agreements to increase AtM in developing countries	Improving Access in the Developing World and Emerging Markets Improving Access to HIV and AIDS Treatment and Care
D2	The company publicly commits itself to respecting the right of developing countries to use the provisions in the TRIPS agreement	Improving Access in the Developing World and Emerging Markets
Drug Manufacturing, Distribution and Capacity Enhancement
E1	The company demonstrates efforts to manufacture drugs to the highest quality standards	Ensuring the Quality of Our Products
E2	The company enters into technology transfer agreements with local companies in developing and least developed countries	Not reported
E3	The company undertakes external activities to support the monitoring of drugs that reflect both the global disease burden and neglected diseases including participation in public private partnerships	Ensuring Confidence in the Safety and Quality of Our Products Improving Access to Vaccines and Immunization Merck MECTIZAN Donation Program Merck Medical Outreach Program
E4	The company has mechanisms in place to help prevent product diversion and to address counterfeiting, in collaboration with states	Anti-Counterfeiting Efforts
E5	The company benefits demonstrate efforts to provide AtM to its employees and their relatives in developing and least developed countries	Fostering the Health and Safety of our Employees
Equitable Pricing
F1	The company can demonstrate efforts to register treatments that reflect both the global disease burden and neglected diseases in developing and least developed countries	Improving Access in the Developing World and Emerging Markets
F2	The company has a policy to facilitate AtM in developing and least developed countries through pricing mechanisms which include reporting on scope, pricing levels and pricing reviews	Improving Access in the Developing World and Emerging Markets
F3	The company demonstrates that its discount schemes place the minimum administrative burden on the beneficiary health system	Improving Access in the Developing World and Emerging Markets U.S. Philanthropic Initiatives and Programs
F4	The company has a policy for the very poorest in countries with no public healthcare provision	U.S. Philanthropic Initiatives and Programs
Drug Donations
G1	The company has a policy that fully conforms to the WHO's Guidelines for Drug Donations	Merck Medical Outreach Program
G2	The company discloses the absolute volume of its drug donations and, to the extent possible, the number of treatments approved for patient use per year	Merck Medical Outreach Program
Philanthropic Activities
H	The company has philanthropic programs related to AtM not covered by any of the other criteria	Improving Access to Medicines, Vaccines and Health Care

The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.

Merck Performance According to the Access to Medicines Index